Meeting
2022 ASCO Annual Meeting
KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.
Authors
Hope S. Rugo
Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Hope S. Rugo , Joohyuk Sohn , Yolanda Jerez Gilarranz , Lucia Gonzalez-Cortijo , Amir Sonnenblick , Dhanusha Sabanathan , Ernesto Pablo Korbenfeld , Daniel Egle , Brigitte Poirier , Flora Zagouri , Alexios Matikas , Sercan Aksoy , Umut Demirci , Pier Ramos-Elias , Seock-Ah Im , Fatima Cardoso , Liyi Jia , Carlos Baccan , Konstantinos Tryfonidis , Peter Schmid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04895358
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS1118)
DOI
10.1200/JCO.2022.40.16_suppl.TPS1118
Abstract #
TPS1118
Poster Bd #
489b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).
First Author: Rebecca Dent
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).
First Author: Javier Cortés
Poster
2023 ASCO Annual Meeting
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.
First Author: Sun Young Rha
Poster
2023 ASCO Annual Meeting
Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW).
First Author: Kohei Shitara